Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. - Wikidata - wikimedia - TriplyDB

Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.

Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.

http://www.wikidata.org/entity/Q37098646

about

Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.Universal Hepatitis C Eradication Prior to Liver Transplantation: We Can Do It, but Should We?Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.

P2860

Q28076547-FB9005B9-1D15-4269-9FDB-B6C35A3435C7 Q38755073-20AD0726-FC45-46BB-9392-F24B3B93A890 Q40271866-E7357686-3FF2-4713-9A54-AC952733BC4A Q40420373-C4233295-5C71-4DFF-8EA8-BFF5AD5BC761 Q40576603-27421D2C-CD40-4BFC-BE1E-2754AE4D35D0 Q42980035-E35C749F-F194-4E43-89DC-5E9700C395FA Q55280669-13EAF1E0-3057-4766-A06A-019432C5D2A3

P2860

Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.

http://www.wikidata.org/entity/Q37098646

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost-Effectiveness of New Dire ...... ransplant Recurrent Hepatitis.

@en

Cost-Effectiveness of New Dire ...... ransplant Recurrent Hepatitis.

@nl

type

label

Cost-Effectiveness of New Dire ...... ransplant Recurrent Hepatitis.

@en

Cost-Effectiveness of New Dire ...... ransplant Recurrent Hepatitis.

@nl

prefLabel

Cost-Effectiveness of New Dire ...... ransplant Recurrent Hepatitis.

@en

Cost-Effectiveness of New Dire ...... ransplant Recurrent Hepatitis.

@nl

P1433

Q37098646-76B0D99E-7537-424E-838D-21BF4DC493A8

P1476

Q37098646-0FBD991C-A93A-4BFF-9A95-C6EB9845993F

P2093

Q37098646-1F5FA90E-7EE0-4BC0-AD2B-195AA72B7E5A

Q37098646-755A8922-56B7-4E75-B8B1-75036D8665B3

Q37098646-FC970264-E9B4-43B7-B190-D2C4337A82CE

Q37098646-FDEE1953-AE8F-418F-93D1-1D42C8FDCDDA

P2860

Q37098646-0D628DE0-9401-4F1D-BD5A-8C99C3141FA6

Q37098646-1A25007E-B6B8-42FC-ADF6-967F2AEE4F31

Q37098646-223D0508-ED1B-42FC-B287-51B7FD3B9C3B

Q37098646-3A937873-5255-4575-BBA6-49A7419F03E9

Q37098646-4A9195AC-FD70-437E-A45E-3ADC329F057F

Q37098646-613C6A16-839E-43E3-90B2-CC83A500F5A6

Q37098646-77717E52-9846-4E67-BCE3-CE9A0E0AEC7C

Q37098646-810A98B3-7CCA-4B4B-8423-7CAA334886CC

Q37098646-9B091996-6B7D-4131-B9D7-0321F50365BA

Q37098646-9FF4AA69-9B07-4F16-8266-42B8B25C1ED8

P304

Q37098646-7163CC63-EBF0-4F34-AF00-ABC3127CE9DC

P31

Q37098646-8A4E81BE-D751-4919-B835-0F5A76826150

P356

Q37098646-22C49C3A-DE3A-41F7-A197-0D47FE1F9D49

P407

Q37098646-1231E188-E69F-4402-97BE-7CE349A66D1B

P433

Q37098646-C75C51C9-E063-4274-98E7-6399FB408485

P478

Q37098646-C2084405-6270-4705-8F84-95D9069982DC

P50

Q37098646-14FFA8E5-EB73-405E-8655-B093DDCCF78F

Q37098646-613635D3-F27C-4D35-888B-7F6B96AF1A07

Q37098646-69955B4F-0C90-4CBE-893C-97D7BE2C6821

Q37098646-C2CB2E6D-715B-458F-A535-D2F8863A7F37

P577

Q37098646-60982889-7EAC-467A-BF22-AA5322469EEB

P5875

Q37098646-5A48775F-829E-4017-AA21-1DC0FFA9A214

P698

Q37098646-928163E7-6543-462B-802B-701CEE438A88

P932

Q37098646-5BFCFBF7-21E6-4EE5-9224-E04271D64D53

P356

P1433

American Journal of Transplantation

P1476

Cost-Effectiveness of New Dire ...... Transplant Recurrent Hepatitis

@en

P2093

C Mazzarelli

http://www.w3.org/2001/XMLSchema#string

G Cesana

http://www.w3.org/2001/XMLSchema#string

L S Belli

http://www.w3.org/2001/XMLSchema#string

M Strazzabosco

http://www.w3.org/2001/XMLSchema#string

P2860

Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.

Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection.

Hepatitis C virus treatment pre- and post-liver transplantation.

Viral hepatitis in liver transplantation.

Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.

P304

1817-1826

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJT.13320

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo G. Mantovani

Paolo A. Cortesi

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278791018

http://www.w3.org/2001/XMLSchema#string

P698

26086300

http://www.w3.org/2001/XMLSchema#string

P932

4946849

http://www.w3.org/2001/XMLSchema#string